LB2101
Extensive-Stage Small Cell Lung Cancer
Key Facts
About Legend Biotech
Legend Biotech's mission is to discover, develop, and commercialize transformative cell therapies for patients with life-threatening diseases, primarily in oncology. Its core achievement is the successful global launch of CARVYKTI® (cilta-cel), a best-in-class CAR-T therapy for multiple myeloma, which has propelled the company to commercial leadership and validated its technology platform. The company's strategy centers on deepening its commercial footprint, advancing a broad pipeline of next-generation cell therapies, and expanding its manufacturing capabilities, all underpinned by a strategic global collaboration with Janssen (Johnson & Johnson).
View full company profileTherapeutic Areas
Other Extensive-Stage Small Cell Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| RYZ101 | RayzeBio | Phase 1/2 |
| LB2102 | Genscript Biotech | Phase 1 |